People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...

Women using estrogen-containing contraceptives vs. not using any systemic hormonal contraceptives had reduced odds for ...

New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...

NBC Today show host Savannah Guthrie has been through a tumultuous year, and it doesn't seem to be getting any better anytime ...

After James Van Der Beek's death, doctors say not enough younger adults are getting tested for colon cancer, even though ...

Savannah Guthrie appeared on the New Year’s Day episode of NBC’s Today despite announcing her break from the show. Guthrie previously revealed she would be undergoing surgery for vocal nodules and a ...

Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations Of 336 ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Tezepelumab-ekko is now approved for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting thymic stromal lymphopoietin and marking its second indication after severe asthma. The phase 3 ...